STAT3 and hepatocellular carcinoma: In malignant tumors, niclosamide inhibits Wnt/β-catenin, STAT3, mTOR, NF-κB, and the BCL2 family to induce tumor cell death in adrenocortical carcinoma, lung cancer cells, leukemia, hepatocellular carcinoma, and breast cancer [25,26,27,30,31].